UCB

Innovation for Specialists Global Biopharma Leader

Headquartered in Brussels, Belgium, UCB is a global biopharmaceutical leader based on a unique blend of innovation, entrepreneurship and proven experience.

UCB is driven by a passionate desire to liberate families living with severe diseases so that they can enjoy normal, everyday lives. The company focuses on severe diseases in the fields of the central nervous system (including epilepsy), inflammation (including allergy), and oncology.

UCB key marketed products are Keppra® (antiepileptic, leader in the USA), Xyzal® and Zyrtec® (antiallergics, world leader), Nootropil® (cerebral function regulator), Tussionex™ (antitussive, leader in the USA), and Metadate™/Equasym XL™ (attention-deficit/hyperactivity disorder). 
UCB has three R & D Centres of Excellence based in Slough (UK), Cambridge (UK) and Braine-l’Alleud (Belgium) and has invested 511 million euro in R & D in 2005. UCB is truly global - 44% percent of worldwide sales are in the USA with a further 38% in Europe, 11% in Japan and 7% in the Rest of World.

Employing 8,500 people and operating in 40 countries, UCB achieved revenues of 2.3 billion euro (+ 10%) in 2005 with profit from continuing operations amounting to €270 million (+ 16%). UCB is listed on Euronext Brussels.

UCB continuously looks for MBAs & post-graduates interested in developing their leadership skills and knowledge of the biopharma industry to position themselves as high potentials and key long-term contributors to UCB.  Furthermore, UCB has developed a specific programme targeted to MBAs & post-graduates job seekers, called “MBA Career Pathway”. To find out more about this programme, visit the UCB microsite hosted on MBA-Exchange.com: http://www.mba-exchange.com